



Alan Dillon, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

29th September 2023

PQ: 39490/23

To ask the Minister for Health whether there are drugs available, or there are any plans to make available, drugs for the long-term illness Hashimoto's thyroiditis, a chronic, long-term, incurable disease, on the HSE reimbursement list; and if he will make a statement on the matter. -Alan Dillon

Dear Deputy Dillon,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 39490/23), which you submitted to the Minister for Health for response.

Medicines are added to the formal Reimbursement List following detailed assessments which include assessment of the clinical evidence, the economic evidence and the budget impact of a decision to reimburse specific indications of a medicine. The Primary Care Reimbursement Service is required to reimburse in line with approved decisions of the HSE and the HSE is required to formally assess each medicines and each specific use of such medicines before reimbursing them.

T3 and T4 hormone replacement therapy such as triiodothyronine and levothyroxine are reimbursed under Community Drug Schemes.

Yours sincerely,

A handwritten signature in black ink that reads 'Suzanne Doyle'.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service